

## **Harnessing B cells for cancer immunotherapy.**

**Yanqiu Li, Shala Yuan and Jiusheng Deng\***

Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, USA.

### **Abstract**

**B cells are a heterogeneous population in immune defense system with multidirectional functions. In cancer patients, B cell infiltrates are associated with a significant increase of overall survival. We have recently developed a GM-CSF and IL-4 derived fusion cytokine named GIFT4, which has the capability to prime naïve B cells into anti-tumor immune effector cells. Herein, we overview current research findings on B cell anti-tumor functions and B cell-based approaches for cancer immunotherapy. We predict that GIFT4-augmented B cells as a potent cellular therapeutic could provide a new approach for cancer immunotherapy.**

**Keywords:** B cells, Tumor microenvironment, GIFT4 fusokine, Cancer immunotherapy.

*Accepted July 25, 2016*

### **Introduction**

#### ***B Cell Functions***

B cells are one of the two adaptive arms partnering with T cells in immune defense system against infections by virus, bacteria, fungi and parasites [1]. Originated from hematopoietic stem cells in bone marrow, B cells contain multiple subsets including antibody-secreting cells, antigen-presenting cells (APC), innate B effector cells and regulatory B cells [2]. As a heterogeneous population, B cells possess multidirectional immune functions. For instance, B cells can produce antigen-specific antibodies in response to infectious pathogens or sterile self-antigens [3]. B cells can also present pathogen-derived antigens to T cells during infections [4]. B effector cells can further produce a variety of immune-stimulatory cytokines such as IL-1, IL-6, IL-12 [5], Granulocyte-macrophage colony-stimulating factor (GM-CSF) [6], augment immune response against infections or promote inflammation in autoimmune diseases [6,7]. In contrast, regulatory B cells secrete immune-suppressive cytokines including IL-10 and transforming growth factor- $\beta$  (TGF- $\beta$ ) to attenuate pro-inflammatory immune response [8]. Emerging evidences show that B cells also have anti-tumor function [9,10]. In preclinical animal model, B cells are required for the successful combined antibody-immunotherapy against murine mesotheliomas [11]. In patients with malignancies, B cells are also found to correlate with a significant increase of overall survival, and higher number of B cell infiltrates lead to better prognosis [12]. However, B cells in particular regulatory B cells can also act as immune-suppressive cells and facilitate tumor immune escape

[13,14]. The dual functional faces of B cells on tumors are likely due to the different B cell subpopulations, which have distinguished phenotypes and secretomes that either inhibit tumor growth or facilitate malignancy [9].

#### ***B Cells in Tumor Microenvironment***

B cells as well as T cells, natural killer cells, monocytes and other immune cells can infiltrate into tumor microenvironment, distributing from the tumor margin to the tumor core. In patients with tongue squamous cell carcinoma, infiltrated B cells are commonly found in the carcinoma stroma with tumor-suppressive effect [12]. In pancreatic ductal adenocarcinoma, human B cells reside in tertiary lymphoid tissue with two distinct infiltrating patterns: scattered or organized [15,16]. High density of organized infiltrating B cells predicts longer survival for patients; highlighting B cells are essential effector cells in the tumor microenvironment of human pancreatic ductal adenocarcinoma [16]. In bladder cancer, human CD20<sup>+</sup> B cells preferentially migrate into the lamina propria area, and have positive correlation with T cell infiltration [17]. Further analyses demonstrated that B cell infiltrates have no link with Foxp3 positive regulatory T cells in tumor microenvironment [17]. Moreover, tertiary lymphoid structures with aggregating B cells are associated with lung cancer prognosis [18]. In patients with gastric cancer, B cells abundantly infiltrate and aggregate in the gastric cancer stromal microenvironment, accompanied with infiltrated T-bet<sup>+</sup> T cells to form a tertiary lymphoid structure surrounding the tumor [19]. Tumor-associated B cells in gastric cancer microenvironment are proliferating and express Ki67. Importantly, infiltrated B cell number

is positively linked to relapse-free survival, and B-cell gene expression is significantly connected with improved outcome [19]. It is found that tumor-infiltrating B cells have beneficial effects on prognosis in patients with tongue squamous cell carcinoma [12], pancreatic adenocarcinoma [16], gastric cancer [19], cutaneous melanoma [20,21], breast cancer [22], ovarian cancer [23] and colorectal cancer [24]. However, the mechanisms by which B cells accumulate in the tumor microenvironment and result in better prognosis are not fully understood. One explanation is that tumor-infiltrating B cells express antigen-presentation molecules and function as professional APC to orchestrate T cell-mediated anti-cancer immunity [25,26]. Another reason could be that infiltrated B cells have potent capacity to produce anti-tumor antigen-specific antibodies, since CD138<sup>+</sup> and immunoglobulin kappa C-positive plasma cells have positive impact on anti-tumor immunity and are related to favorable prognosis in cancer patients [24,27]. MUC1 (The polymorphic epithelial mucin) is one of the most specific tumor-associated antigens in human cancers [24,28]. Anti-MUC1 IgG antibodies but not IgM in patients are significantly related to better prognosis [22]. Consistently, high density of plasma cells was found surrounding the tertiary lymphoid structures and correlated to T cell cytotoxicity [29]. Infiltrating B cells can also undergo somatic mutation, clonal expansion, intraclonal variation and isotype switching, eliciting humoral immunity against tumors [30,31]. Collectively, the preclinical and clinical investigations strongly support the notion that B cell infiltrates in the tumor microenvironment not only serve as a valuable predictive biomarker, but also play a profound protective role in anti-tumor immunity [32-35].

### **Cancer Immunotherapy**

During the last decade, great progress has been made on cancer immunotherapy including dendritic cell-based cell immunotherapy [36], chimeric antigen receptor (CAR)-T cell [37,38] and immune checkpoint blockade including CTLA-4 (Cytotoxic T-lymphocyte-associated protein 4) or PD-1 (Programmed cell death protein 1)/PD-L1 (Programmed death-ligand 1) inhibitors [39-41]. Dendritic cells as the most professional APC possess the capability to orchestrate innate and adaptive cellular and humoral immune responses against cancer cells. Cancer-antigen loaded or bioengineered dendritic cells that expressing tumor antigens have been utilized as cancer vaccines for cancer patients [42]. However dendritic cells as a tumor vaccine in clinical trials are not as effective as in preclinical animal tumor models, with the limitation of high-cost, small number and short life (2-3 days after maturation) of dendritic cells generated from peripheral blood monocytes. CAR-T cells have been successfully used to treat B-cell malignancies by targeting CD19, CD20, CD22, CD30, CD33, CD123, CD133, CD138, ROR1,  $\kappa$  light chain and B-cell maturation antigen [43]. The killing of normal B cells besides malignant B cells by CAR-T

cells and its serious treatment-related toxicities remains a challenge [44]. Current clinical trials reveal that CAR-T therapy have very limited efficacy on nonhematological solid tumors. Expression of regulatory molecules such as CTLA-4 and PD-1 on cytotoxic T cells has been shown to suppress the anti-tumor functions of T cells. Thus immune checkpoint blockade using antagonistic antibodies against the negative regulators can overcome cancer immune resistance and demonstrates promising therapeutic efficacy [45-47]. However, clinical trials showed that only partial cancer patients respond to immune checkpoint blockade [48,49]. B cells have multiple functions as antibody-producing cells; antigen-presenting cells, immune effector cells, and are required for adaptive T cell immune responses against tumors [50]. B cells also have an advantage to be easily expanded *ex vivo* in comparison with dendritic cells. Moreover, activated B cells can effectively present tumor lysate, antigen peptide or antigen cDNA and induce antigen-specific T cell immunoreaction against tumors [51]. Thus, B cells represent a promising approach for cancer immunotherapy, complementing the use of dendritic cells.

### **B Cell Based Approaches for Cancer Immunotherapy**

B cells have been widely explored as a cellular adjuvant for cancer immunotherapy due to its immune-stimulatory activities. As antigen-presenting cells, B cells express CD40 and ligation with CD40 ligand on B cells robustly enhances the expression of co-stimulatory molecules CD80 and CD86 [52]. Consequently, CD40-activated B cells have potent capability to promote naïve and memory T activation and expansion and induce cytotoxic T cells immunity [53]. When pulsed with a melanoma antigen, CD40-activated B cells efficiently propel the generation of melanoma-specific T cells *in vitro* [54]. CD40-activated B cells also express adhesion molecules and chemokine receptors facilitating the cells to migrate into the secondary lymphoid organs, attract and interact with antigen-specific T cells [52-55]. CD40-activated B cells also function similarly to plasma cells and produce IgG [52]. *In vivo*, CD40-activated B cells have protective effect on various tumor models [56,57], with little toxicity to the mice [56]. Alternatively, CD40-ligated B cells loaded with tumor-specific RNA as a cancer vaccine induce tumor-specific cytotoxic T cell immune response, inhibit the growth of non-Hodgkin's lymphoma and improve overall survival in preclinical animal model [57]. It is interesting that leukemia B cells activated by CD40 ligation are also functionally similar to antigen-presenting cells and induce both IFN- $\gamma$ <sup>+</sup> CD4 and cytotoxic CD8 T cell proliferating and expansion [58]. Those data together inform that CD40-activated B cells have the potential to serve as a potent cellular agent for cancer immunotherapy.


Tumor-infiltrated B cells provide another approach for B cell cancer immunotherapy. B cells infiltrated into tumor stroma function as both antigen-presenting cells and tumor antigen-specific antibody-producing cells,

and play essential roles in anti-tumor immunity [34,59]. A Epstein-Barr virus immortalization *in vitro* assay demonstrates that primary colorectal carcinoma harbor infiltrated B cells that are consistent of CD23<sup>+</sup>CD80<sup>+</sup> activated antigen-presenting cells and IgG-secreting cells. Those infiltrated B cells not only produce functional carcinoma-specific antibodies [59], but are also associated with cytolytic T cell response and superior prognosis in cancers [21,22,24,29]. Adoptive transfer of tumor-derived B cells further promotes anti-tumor T cell immunity and leads to tumor regression in preclinical breast cancer and pulmonary metastatic tumor animal models [60,61]. The anti-tumor property of tumor-primed B cells suggests that *ex vivo* expanded tumor-primed B cells could be utilized as potent T helper cells for cancer immunotherapy. B cells loaded with tumor-derived autophagosomes have the ability to present tumor-specific antigens selectively captured by autophagosomes and induce robust anti-tumor T cell response as well as antibody-mediated humoral response [62]. Administration of tumor-antigen loaded B cells as a vaccine further prevents the growth of tumors in mice [62], indicating that B cells activated by tumor-derived autophagosomes represent a new strategy for cancer immunotherapy.

Recently, we have developed an immune-stimulatory fusion cytokine (Fusokine) named GIFT4 (Figure 1), which is a granulocyte macrophage colony-stimulating factor (GM-CSF) and common  $\gamma$ -chain Interleukins 4 (IL-4) fusion transgene [63]. In comparison with its parental cytokines, GIFT4 fusokine gains new function distinct from its parental cytokines GM-CSF and IL-4. GIFT4 has potent capability to activate and program naive B cells into immune effector cells. Programming of naïve B cells by GIFT4 fusokine involves both GM-CSF and IL-4 domains through a synergistic recruitment of GM-CSF receptor and IL-4 receptor clustered on B cell surface, which further triggers the formation of downstream signaling complex of JAK1 (The Janus kinase 1), 2, 3 and STAT1 (The signal transducer and activator of transcription 1), 3, 5 and 6 [63]. Inhibition of JAK signaling by its specific inhibitors completely interrupted GIFT4-induced STAT1, STAT3, STAT5 and STAT6 signaling in the treated B cells

and consequent B cell expansion. In contrast, combined use of parental cytokines GM-CSF and IL-4 is unable to cluster the two receptors on B cell surface and induce B cell proliferation.

Interesting, GIFT4 protein has no effect on monocytes, although GM-CSF and IL-4 together have the capability to promote monocytes differentiation into dendritic cells. GIFT4-augmented B cells (GIFT4-B cells) express co-stimulatory molecules CD40, CD80 and CD86, and produce unique immune-stimulatory cytokines, chemokines and adhesion molecules including IL-1 $\alpha$ , IL-6, IL-12, GM-CSF, CCL3, CCL4 and CD54, but little IL-10 and IFN- $\gamma$  [63], apart from CD40-activated B cells [52] or innate response activator B cells [6]. With those immune properties, GIFT4-B cells function as APC-like effector cells, and consequently promote the expansion of CD314<sup>+</sup>, granzyme B-, granulysin- and IFN- $\gamma$ -producing cytotoxic T cells that selectively kill human melanoma cells both *in vitro* and *in vivo* [63]. Moreover, GIFT4 fusokine induces B cell-dependent anti-tumor immunity in murine melanoma models [63], involving both APC-like B effector cells and GM-CSF-producing innate response activator B-cells [6,63]. In our investigation of GIFT4 as a potential vaccine adjuvant, we also discovered that GIFT4-coated virus-like particles enhance anti-HIV antigen-specific antibody production *in vivo* [64], suggesting additional effect of GIFT4 on the antibody-secreting cells. Indeed, we have found that administration of GIFT4 protein induces robust anti-melanoma specific-antibody production in murine melanoma model (Unpublished data). We have further extended our investigation to human chronic lymphocytic leukemic (CLL) B cells, and examined the immune activity of GIFT4-stimulated CLL B cells (GIFT4-CLL cells). Unlike CD40-activated CLL cells [58], TLR9 ligand-treated CLL cells [65] or normal GIFT4-B cells [63], GIFT4-CLL cells produce immune-stimulatory cytokines including IL-1 $\beta$ , IL-2, IL-6, IL-8, ICAM-1 and prime autologous T cells to proliferate, express tumor-killing molecules IFN- $\gamma$ , CD314, perforin and granzyme B, and lyse autologous primary leukemic cells [66]. Taken together, GIFT4 induces broad anti-tumor B cell immune



**Figure 1.** Structure of GIFT4 protein. (A) GIFT4 protein structure that contains GM-CSF and IL-4 domains. (B) Amino acids of human GIFT4

responses either through GIFT4-programmed B effector cells that further prime tumor-killing cytotoxic T cell response, or through the augmentation of tumor-specific antibody production. Those results provide a strong basis for the potential utilization of GIFT4 fusokine and GIFT4-augmented B cells as well as GIFT4-converted CLL cells for cancer immunotherapy in human.

## **Conclusion**

B cells play pivotal roles in immune defense system, which bridge the innate and the adaptive immunities against cancers. Augmented B cells including GIFT4-B cells and expanded tumor-infiltrated B cells have potent immune-stimulatory activities and anti-tumor function by either priming cytotoxic T cell response or producing anti-tumor specific antibodies. We predict that GIFT4 and GIFT4-augmented B cells as potential immune therapeutics could provide a new approach for cancer immunotherapy.

## **Acknowledgement**

This work was supported by the Winship Robbins Scholar Award, the Winship Melanoma Research Fund and the Developmental Fund of the Winship Cancer Center Support Grant (5P30CA138292-06) (to JD).

## **Disclosure**

The authors declare that they have no competing interest.

## **References**

1. Cooper MD. The early history of B cells. *Nature reviews Immunology* 2015; 15: 191-197.
2. Borhis G, Richard Y. Subversion of the B-cell compartment during parasitic, bacterial and viral infections. *BMC Immunology* 2015, 16: 15.
3. Khan WN, Wright JA, Kleiman E, et al. B-lymphocyte tolerance and effector function in immunity and autoimmunity. *Immunologic Research* 2013; 57: 335-353.
4. Popi AF, Longo-Maugeri IM, Mariano M. An overview of B-1 cells as antigen-presenting cells. *Frontiers in Immunology* 2016; 7: 138.
5. Bao Y, Cao X. The immune potential and immunopathology of cytokine-producing B cell subsets: A comprehensive review. *Journal of Autoimmunity* 2014; 55: 10-23.
6. Rauch PJ, Chudnovskiy A, Robbins CS, et al. Innate response activator B cells protect against microbial sepsis. *Science* 2012; 335: 597-601.
7. Zasada M, Rutkowska-Zapala M, Lenart M, et al. The role of IRA B cells in selected inflammatory processes. *Postepy higieny i medycyny doswiadczalnej* 2016; 70: 194-199.
8. Rosser EC, Mauri C. Regulatory B cells: Origin, phenotype and function. *Immunity* 2015; 42: 607-612.
9. Wang JZ, Zhang YH, Guo XH, et al. The double-edge role of B cells in mediating antitumor T-cell immunity: Pharmacological strategies for cancer immunotherapy. *International Immunopharmacology* 2016; 36: 73-85.
10. Garnelo M, Tan A, Her Z, et al. Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma. *Gut* 2015.
11. Krishnan S, Bakker E, Lee C, et al. Successful combined intratumoral immunotherapy of established murine mesotheliomas require B-cell involvement. *Journal of interferon & cytokine research: The Official Journal of the International Society for Interferon and Cytokine Research* 2015; 35: 100-107.
12. Lao XM, Liang YJ, Su YX, et al. Distribution and significance of interstitial fibrosis and stroma-infiltrating B cells in tongue squamous cell carcinoma. *Oncology Letters* 2016; 11: 2027-2034.
13. Zhang Y, Gallastegui N, Rosenblatt JD. Regulatory B cells in anti-tumor immunity. *International Immunology* 2015; 27: 521-530.
14. Tang A, Dadaglio G, Oberkamp M, et al. B cells promote tumor progression in a mouse model of HPV-mediated cervical cancer. *International Journal of Cancer* 2016.
15. Hiraoka N, Ino Y, Yamazaki-Itoh R, et al. Intratumoral tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer. *British Journal of Cancer* 2015; 112: 1782-1790.
16. Castino GF, Cortese N, Capretti G, et al. Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma. *Oncoimmunology* 2016; 5: e1085147.
17. Pichler R, Fritz J, Zavadil C, et al. Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical bacillus calmette-guerin therapy in bladder cancer. *Oncotarget* 2016.
18. Goc J, Fridman WH, Sautes-Fridman C, et al. Characteristics of tertiary lymphoid structures in primary cancers. *Oncoimmunology* 2013; 2: e26836.
19. Hennequin A, Derangere V, Boidot R, et al. Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients. *Oncoimmunology* 2016; 5: e1054598.
20. Ladanyi A. Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma. *Pigment Cell & Melanoma Research* 2015; 28: 490-500.
21. Garg K, Maurer M, Griss J, et al. Tumor associated B cells in cutaneous primary melanoma and improved clinical outcome. *Human pathology* 2016.
22. Fremd C, Stefanovic S, Beckhove P, et al. Mucin 1-specific B cell immune responses and their impact on overall survival in breast cancer patients. *Oncoimmunology* 2016; 5: e1057387.
23. Lundgren S, Berntsson J, Nodin B, et al. Prognostic impact of tumour-associated B cells and plasma cells in epithelial ovarian cancer. *Journal of Ovarian Research* 2016; 9: 21.
24. Berntsson J, Nodin B, Eberhard J, et al. Prognostic impact of tumour-infiltrating B cells and plasma cells in colorectal cancer. *International Journal of Cancer* 2016; 139: 1129-1139.
25. Nielsen JS, Sahota RA, Milne K, et al. CD20+ tumor-

- infiltrating lymphocytes have an atypical CD27-memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. *Clinical Cancer Research: An Official JAACR* 2012; 18: 3281-3292.
26. Nielsen JS, Nelson BH. Tumor-infiltrating B cells and T cells: Working together to promote patient survival. *Oncoimmunology* 2012; 1: 1623-1625.
  27. Lohr M, Edlund K, Botling J, et al The prognostic relevance of tumour-infiltrating plasma cells and immunoglobulin kappa C indicates an important role of the humoral immune response in non-small cell lung cancer. *Cancer Letters* 2013; 333: 222-228.
  28. Yokoyama S, Higashi M, Kitamoto S, et al. Aberrant methylation of MUC1 and MUC4 promoters are potential prognostic biomarkers for pancreatic ductal adenocarcinomas. *Oncotarget* 2016.
  29. Kroeger DR, Milne K, Nelson BH. Tumor-infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic T-cell responses and superior prognosis in ovarian cancer. *Clinical cancer research. Ameri Asso Can Res* 2016; 22: 3005-3015.
  30. Campa MJ, Moody MA, Zhang R, et al. Interrogation of individual intratumoral B lymphocytes from lung cancer patients for molecular target discovery. *Cancer Immunology, Immunotherapy* 2016; 65: 171-180.
  31. Quan H, Fang L, Pan H, et al An adaptive immune response driven by mature, antigen-experienced T and B cells within the microenvironment of oral squamous cell carcinoma. *International Journal of Cancer* 2016; 138: 2952-2962.
  32. Bremnes RM, Busund LT, Kilvaer TL, et al. The role of tumor-infiltrating lymphocytes in development, progression and prognosis of non-small cell lung cancer. *Journal of Thoracic Oncology. International Association for the Study of Lung Cancer* 2016; 11: 789-800.
  33. Dieu-Nosjean MC, Giraldo NA, Kaplon H, et al. Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers. *Immunological Reviews* 2016; 271: 260-275.
  34. Germain C, Gnjatic S, Dieu-Nosjean MC. Tertiary lymphoid structure-associated B cells are key players in anti-tumor immunity. *Frontiers in Immunology* 2015; 6: 67.
  35. Muenst S, Laubli H, Soysal SD, et al. The immune system and cancer evasion strategies: Therapeutic concepts. *Journal of Internal Medicine* 2016; 279: 541-562.
  36. Ni M, Hoffmann JM, Schmitt M, et al. Progress of dendritic cell-based cancer vaccines for patients with hematological malignancies. *Expert Opinion on Biological Therapy* 2016; 1-11.
  37. Haji-Fatahaliha M, Hosseini M, Akbarian A, et al. CAR-modified T-cell therapy for cancer: An updated review. *Artificial Cells, Nanomedicine and Biotechnology* 2015; 1-11.
  38. Zhang H, Ye ZL, Yuan ZG, et al. New strategies for the treatment of solid tumors with CAR-T cells. *International Journal of biological sciences* 2016; 12: 718-729.
  39. Kyi C, Postow MA. Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges. *Immunotherapy* 2016; 8: 821-837.
  40. Adachi K, Tamada K. Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. *Cancer science* 2015; 106: 945-950.
  41. Lee CS, Cragg M, Glennie M, Johnson P. Novel antibodies targeting immune regulatory checkpoints for cancer therapy. *British journal of clinical pharmacology* 2013; 76: 233-247.
  42. Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. *Immunity* 2013; 39: 38-48.
  43. Almasbak H, Aarvak T, Vemuri MC. CAR T cell Therapy: A Game Changer in Cancer Treatment. *Journal of immunology research* 2016; 2016: 5474602.
  44. Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. *Blood* 2016.
  45. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. *The New England journal of medicine* 2014; 371: 2189-2199.
  46. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *The New England journal of medicine* 2012; 366: 2443-2454.
  47. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. *The New England journal of medicine* 2012; 366: 2455-2465.
  48. Wargo JA, Cooper ZA, Flaherty KT. Universes collide: combining immunotherapy with targeted therapy for cancer. *Cancer discovery* 2014; 4: 1377-1386.
  49. Robert L, Ribas A, Hu-Lieskovan S. Combining targeted therapy with immunotherapy. *Can 1+1 equal more than 2? Seminars in immunology* 2016; 28: 73-80.
  50. DiLillo DJ, Yanaba K, Tedder TF. B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. *Journal of immunology* 2010; 184: 4006-4016.
  51. Guo S, Xu J, Denning W, Hel Z. Induction of protective cytotoxic T-cell responses by a B-cell-based cellular vaccine requires stable expression of antigen. *Gene therapy* 2009; 16: 1300-1313.
  52. Wennhold K, Shimabukuro-Vornhagen A, Theurich S, von Bergwelt-Baildon M. CD40-activated B cells as antigen-presenting cells: the final sprint toward clinical application. *Expert review of vaccines* 2013; 12: 631-637.
  53. Gonzalez NK, Wennhold K, Balkow S, Kondo E, Bolck B, et al. Imaging of initial B-T-cell interactions in the setting of B-cell based cancer immunotherapy. *Oncoimmunology* 2015; 4: e1038684.
  54. Lapointe R, Bellemare-Pelletier A, Housseau F, et al. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. *Cancer research* 2003; 63: 2836-2843.

55. von Bergwelt-Baildon M, Shimabukuro-Vornhagen A, Popov A, et al. CD40-activated B cells express full lymph node homing triad and induce T-cell chemotaxis: Potential as cellular adjuvants. *Blood* 2006; 107: 2786-2789.
56. Wennhold K, Weber TM, Thelen M, et al. CD40-activated B cells induce anti-tumor immunity *in vivo*. *Oncotarget* 2016.
57. Sorenmo KU, Krick E, Coughlin CM, et al. CD40-activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with non-Hodgkin's lymphoma. *PLoS One* 2011; 6: e24167.
58. Buhmann R, Nolte A, Westhaus D, et al. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells. *Blood* 1999; 93: 1992-2002.
59. Maletzki C, Jahnke A, Ostwald C, et al. *Ex vivo* clonally expanded B lymphocytes infiltrating colorectal carcinoma is of mature immunophenotype and produce functional IgG. *PLoS One* 2012; 7: e32639.
60. Li Q, Lao X, Pan Q, et al. Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression. *Clinical Cancer Research: An Official Journal of the American Association for Cancer Research* 2011; 17: 4987-4995.
61. Li Q, Teitz-Tennenbaum S, Donald EJ, et al. *In vivo* sensitized and *in vitro* activated B cells mediate tumor regression in cancer adoptive immunotherapy. *Journal of Immunology* 2009; 183: 3195-3203.
62. Ren H, Zhao S, Li W, et al. Therapeutic antitumor efficacy of B cells loaded with tumor-derived autophagosomes vaccine (DRibbles). *Journal of Immunotherapy* 2014; 37: 383-393.
63. Deng J, Yuan S, Pennati A, et al. Engineered fusokine GIFT4 licenses the ability of B cells to trigger a tumoricidal T-cell response. *Cancer Research* 2014; 74: 4133-4144.
64. Feng H, Zhang H, Deng J, et al. Incorporation of a GPI-anchored engineered cytokine as a molecular adjuvant enhances the immunogenicity of HIV VLPs. *Scientific Reports* 2015; 5: 11856.
65. Ghamlouch H, Ouled-Haddou H, Guyart A. TLR9 Ligand (CpG Oligodeoxynucleotide) induces CLL B-cells to differentiate into CD20(+) antibody-secreting cells. *Frontiers in Immunology* 2014; 5: 292.
66. Deng J, Pennati A, Cohen JB, et al. GIFT4 fusokine converts leukemic B cells into immune helper cells. *Journal of translational medicine* 2016; 14: 106.

**Correspondence to:**

Jiusheng Deng,  
Department of Hematology and Medical Oncology,  
Winship Cancer Institute,  
Emory University,  
1365B Clifton Road,  
Atlanta, GA,  
USA.  
Tel: 4047781763  
E-mail: [jdeng2@emory.edu](mailto:jdeng2@emory.edu)